Amendments to the Claims:

This listing of claims will replace all previous versions and listings of claims in the

application:

1-12. (withdrawn)

13. (currently amended) An <u>isolated</u> antibody which specifically binds to a

polypeptide according to claim 10 of SEQ ID NO:20, wherein said reduces the severity of an

immune-related disease associated with the overexpression of PRO19600.

14. (original) The antibody of claim 13, wherein said antibody is a monoclonal

antibody, a humanized antibody or a single-chain antibody.

15. (currently amended) A composition of matter comprising (a) a polypeptide of

claim 10, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an

antibody that binds to said polypeptide of claim 13, in combination with a carrier.

16. (original) The composition of matter of claim 15, wherein said carrier is a

pharmaceutically acceptable carrier.

17. (currently amended) The composition of matter of claim 16 comprising a

therapeutically effective amount of (a), (b), (c) or (d) the antibody of claim 13.

18.-26. (withdrawn)

-2-

Amendment and Response to Office Action (Dated: April 7, 2008 – Paper No./Mail Date 20080318)
Application Serial No. 10/527.101

Attorney's Docket No. GNE-0266 R1